nach oben

Erschienen in:

14.10.2017

Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review

verfasst von: Fabienne Langlois, Dawn Shao Ting Lim, Chris G. Yedinak, Isabelle Cetas, Shirley McCartney, Justin Cetas, Aclan Dogan, Maria Fleseriu

Erschienen in: Pituitary | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Silent corticotroph adenomas (SCAs) are clinically silent and non-secreting, but exhibit positive adrenocorticotropic hormone (ACTH) immunostaining. We characterized a single center cohort of SCA patients, compared the SCAs to silent gonadotroph adenomas (SGAs), identified predictors of recurrence, and reviewed and compared the cohort to previously published SCAs cases.

Methods

Retrospective review of SCA and SGA surgically resected patients over 10 years and 6 years, respectively. Definitions; SCA—no clinical or biochemical evidence of Cushing’s syndrome and ACTH positive immunostaining, and SGA—steroidogenic factor (SF-1) positive immunostaining. A systematic literature search was undertaken using Pubmed and Scopus.

Results

Review revealed 814 pituitary surgeries, 39 (4.8%) were SCAs. Mean follow-up was 6.4 years (range 0.5–23.8 years). Pre-operative magnetic resonance imaging demonstrated sphenoid and/or cavernous sinus invasion in 44%, 33% were > 50% cystic, and 28% had high ACTH levels pre-operatively. Compared to SGAs (n = 70), SCAs were of similar size and invasiveness (2.5 vs. 2.9 cm, p = 0.2; 44 vs. 41%, p = 0.8, respectively), but recurrence rate was higher (36 vs. 10%, p = 0.001) and more patients received radiation therapy (18 vs. 3%, p = 0.006). Less cystic tumors (0 vs. 50%, p < 0.001) and higher pre-operative ACTH levels (54 vs. 28 pg/ml, p = 0.04) were predictors of recurrence for SCAs.

Conclusion

This review is unique; a strict definition of SCA was used, and single center SCAs were compared with SGAs and with SCAs literature reviewed cases. We show that SCAs are aggressive and identify predictors of recurrence. Accurate initial diagnosis, close imaging and biochemical follow up are warranted.

Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W (1980) Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 98(3):617–638PubMedPubMedCentral

Kovacs K, Horvath E, Bayley TA, Hassaram ST, Ezrin C (1978) Silent corticotroph cell adenoma with lysosomal accumulation and crinophagy. A distinct clinicopathologic entity. Am J Med 64(3):492–499CrossRefPubMed

Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203–216CrossRefPubMed

Cooper O (2015) Silent corticotroph adenomas. Pituitary 18(2):225–231CrossRefPubMedPubMedCentral

Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Lloyd RV, Meyer FB, Laws ER Jr, Young WF Jr (2000) Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 47(3):723–729PubMed

Webb KM, Laurent JJ, Okonkwo DO, Lopes MB, Vance ML, Laws ER (2003) Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery 53(5):1076–1085CrossRefPubMed

Cho HY, Cho SW, Kim SW, Shin CS, Park KS, Kim SY (2010) Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clin Endocrinol 72(5):648–653CrossRef

Bradley KJ, Wass JA, Turner HE (2003) Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol 58(1):59–64CrossRef

Baldeweg SE, Pollock JR, Powell M, Ahlquist J (2005) A spectrum of behaviour in silent corticotroph pituitary adenomas. Br J Neurosurg 19(1):38–42CrossRefPubMed

10.

Abe M, Sawabe Y, Mochizuki Y, Sunaga S, Izumiyama H, Matsumoto K, Kushima M, Taniyama M, Ban Y, Sano T (2001) Corticotroph cell adenoma without typical manifestations of Cushing’s disease presenting with cavernous sinus syndrome following pituitary apoplexy. Endocr J 48(4):503–507CrossRefPubMed

11.

Alahmadi H, Lee D, Wilson JR, Hayhurst C, Mete O, Gentili F, Asa SL, Zadeh G (2012) Clinical features of silent corticotroph adenomas. Acta Neurochir 154(8):1493–1498CrossRef

12.

Al-Sarraj S, King A, Harris P, Lantos P (2002) Atypical pituitary adenoma (silent corticotroph pituitary adenoma). Neuropathol Appl Neurobiol 28(2):157–158CrossRef

13.

Ambrosi B, Colombo P, Bochicchio D, Bassetti M, Masini B, Faglia G (1992) The silent corticotropinoma: is clinical diagnosis possible? J Endocrinol Invest 15(6):443–452CrossRefPubMed

14.

Benaiges D, Puig J, Lafuente J, Gimeno J, Prados M, Sagarra E, Flores-Le-Roux J (2012) Biochemical behaviour of an incidentally diagnosed silent corticotroph adenoma. Neuro Endocrinol Lett 33(3):290–293PubMed

15.

Bordo G, Duong H, McLaughlin N, Cornell R, Findling J, Kelly D (2012) Case report: silent corticotroph adenoma progressing to cushing’s disease then to pituitary carcinoma with dramatic treatment response. J Neurol Surg Part B 73:02

16.

Braithwaite SS, Clasen RA, D’Angelo CM (1997) Silent corticotroph adenoma: case report and literature review. Endocr Pract 3(5):297–301CrossRefPubMed

17.

Brown RL, Wollman R, Weiss RE (2007) Transformation of a pituitary macroadenoma into to a corticotropin-secreting carcinoma over 16 years. Endocr Pract 13(5):463–471CrossRefPubMed

18.

Cazabat L, Dupuy M, Boulin A, Bernier M, Baussart B, Foubert L, Raffin-Sanson ML, Caron P, Bertherat J, Gaillard S (2014) Silent, but not unseen: multimicrocystic aspect on T2-weighted MRI in silent corticotroph adenomas. Clin Endocrinol 81(4):566–572CrossRef

19.

Chen SC, Chung WY (2015) Progression rate of silent corticotroph adenomas after stereotactic radiosurgery. In regard to Xu et al. Int J Radiat Oncol Biol Phys 91(5):1113–1114CrossRefPubMed

20.

Coire CI, Horvath E, Kovacs K, Smyth HS, Sasano H, Iino K, Feig DS (1998) A composite silent corticotroph pituitary adenoma with interspersed adrenocortical cells: case report. Neurosurgery 42(3):650–654CrossRefPubMed

21.

Cooper ME, Murray RM, Kalnins R, Woodward J, Jerums G (1987) The development of Cushing’s syndrome from a previously silent pituitary tumour. Aust N Z J Med 17(2):249–251CrossRefPubMed

22.

Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S (2010) Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer 1(2):80–92CrossRefPubMedPubMedCentral

23.

Fang H, Tian R, Wu H, Xu J, Fan H, Zhou J, Zhong L (2015) Cushing disease after treatment of nonfunctional pituitary adenoma: a case report and literature review. Medicine 94(51):e2134CrossRef

24.

Farrell WE, Coll AP, Clayton RN, Harris PE (2003) Corticotroph carcinoma presenting as a silent corticotroph adenoma. Pituitary 6(1):41–47CrossRefPubMed

25.

Felix I, Asa SL, Kovacs K, Horvath E (1991) Changes in hormone production of a recurrent silent corticotroph adenoma of the pituitary: a histologic, immunohistochemical, ultrastructural, and tissue culture study. Hum Pathol 22(7):719–721CrossRefPubMed

26.

Gheri RG, Boddi W, Ammannati F, Olivotto J, Nozzoli C, Franchi A, Bordi L, Luisi ML, Mennonna P (1997) Two-step development of a pituitary adenoma: from hyperprolactinemic syndrome to Cushing’s disease. J Endocrinol Invest 20(4):240–244CrossRefPubMed

27.

Ghervan C (2014) Silent corticotroph adenoma transformed in secreting adenoma with severe Cushing’s disease after two pituitary surgeries. Acta Endocrinol 10(2):283–292

28.

Gibson S, Ray DW, Crosby SR, Dornan TL, Jennings AM, Bevan JS, Davis JR, White A (1996) Impaired processing of proopiomelanocortin in corticotroph macroadenomas. J Clin Endocrinol Metab 81(2):497–502PubMed

29.

Gogel EL, Salber PR, Tyrrell JB, Rosenblum ML, Findling JW (1983) Cushing’s disease in a patient with a ‘nonfunctioning’ pituitary tumor: spontaneous development and remission. Arch Intern Med 143(5):1040–1042CrossRefPubMed

30.

Guttenberg KB, Mayson SE, Sawan C, Kharlip J, Lee JY, Martinez-Lage M, Loevner LA, Ewanichak J, Grady MS, Snyder PJ (2016) Prevalence of clinically silent corticotroph macroadenomas. Clin Endocrinol 85(6):874–880CrossRef

31.

He L, Forbes JA, Carr K, Highfield Nickols H, Utz A, Moots P, Weaver K (2016) Response of silent corticotroph pituitary carcinoma to chemotherapy: case report. J Neurosurg Sci 60(2):272–280PubMed

32.

Ikeda H, Yoshimoto T, Kovacs K, Horvath E (1995) Cushing’s disease due to female gonadotroph adenoma of the pituitary. Clin Endocrinol 43(3):383–386CrossRef

33.

Ioachimescu AG, Eiland L, Chhabra VS, Mastrogianakis GM, Schniederjan MJ, Brat D, Pileggi AV, Oyesiku NM (2012) Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas. Neurosurgery 71(2):296–303CrossRefPubMed

34.

Jahangiri A, Wagner JR, Pekmezci M, Hiniker A, Chang EF, Kunwar S, Blevins L, Aghi MK (2013) A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 73(1):8–17CrossRefPubMed

35.

Kojima Y, Suzuki S, Yamamura K, Ohhashi G, Yamamoto I (2002) Comparison of ACTH secretion in Cushing’s adenoma and clinically silent corticotroph adenoma by cell immunoblot assay. Endocr J 49(3):285–292CrossRefPubMed

36.

Iino K, Oki Y, Matsushita F, Yamashita M, Hayashi C, Miura K, Nishizawa S, Nakamura H (2007) Immunohistochemical properties of silent corticotroph adenoma and Cushing’s disease. Pituitary 10(1):35–45CrossRefPubMed

37.

Lipatenkova A, Dzeranova L, Pigarova E, Ektova A (2014) Clinical case: silent corticotroph pituitary macroadenoma transforming into Cushing disease. Endocr Abstr. doi:10.1530/endoabs.35.P915

38.

Lopez JA, Kleinschmidt-Demasters BK, Sze C-I, Woodmansee WW, Lillehei KO (2004) Silent corticotroph adenomas: Further clinical and pathological observations. Hum Pathol 35(9):1137–1147CrossRefPubMed

39.

Matsuno A, Okazaki R, Oki Y, Nagashima T (2004) Secretion of high-molecular-weight adrenocorticotropic hormone from a pituitary adenoma in a patient without Cushing stigmata: case report. J Neurosurg 101(5):874–877CrossRefPubMed

40.

Mindermann T, Kovacs K, Wilson CB (1994) Changes in the immunophenotype of recurrent pituitary adenomas. Neurosurgery 35(1):39–44CrossRefPubMed

41.

Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K (2011) Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Hormones 10(2):162–167CrossRef

42.

Ohta S, Nishizawa S, Oki Y, Yokoyama T, Namba H (2002) Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I–immunohistochemical study. Pituitary 5(4):221–223CrossRefPubMed

43.

Pawlikowski M, Kunert-Radek J, Radek M (2008) “Silent" corticotropinoma. Neuro Endocrinol Lett 29(3):347–350PubMed

44.

Psaras T, Honegger J, Buslei R, Saeger W, Klein D, Capper D, Meyermann R, Mittelbronn M (2007) Atypical type II silent corticotrophic adenoma developing into Cushing’s disease upon second recurrence. Exp Clin Endocrinol Diabetes 115(9):610–615CrossRefPubMed

45.

Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J, Pugeat M, Trouillas J (2010) Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing’s disease. Eur J Endocrinol 163(1):35–43CrossRefPubMed

46.

Reincke M, Allolio B, Saeger W, Kaulen D, Winkelmann W (1987) A pituitary adenoma secreting high molecular weight adrenocorticotropin without evidence of Cushing’s disease. J Clin Endocrinol Metab 65(6):1296–1300CrossRefPubMed

47.

Righi A, Faustini-Fustini M, Morandi L, Monti V, Asioli S, Mazzatenta D, Bacci A, Foschini MP (2017) The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3. Endocr 56(2):286–297CrossRef

48.

Sakaguchi H, Koshiyama H, Sano T, Inoue D, Hashimoto N, Aoki N, Nakao K (1997) A case of nonfunctioning pituitary adenoma resembling so-called silent corticotroph adenoma. Endocr J 44(2):329–333CrossRefPubMed

49.

Sano T, Kovacs K, Asa SL, Yamada S, Sanno N, Yokoyama S, Takami H (2002) Pituitary adenoma with “honeycomb Golgi” appearance showing a phenotypic change at recurrence from clinically nonfunctioning to typical Cushing disease. Endocr Pathol 13(2):125–130CrossRefPubMed

50.

Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapıcıer Ö, Young WF, Meyer FB, Kuroki T, Riehle DL, Laws ER (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59(2):341–353CrossRefPubMed

51.

Serri O, Robert F, Pelletier G, Beauregard H, Hardy J (1987) Hyperprolactinemia associated with clinically silent adenomas: endocrinologic and pathologic studies; a report of two cases. Fertil Steril 47(5):792–796CrossRefPubMed

52.

Tan EU, Ho MS, Rajasoorya CR (2000) Metamorphosis of a non-functioning pituitary adenoma to Cushing’s disease. Pituitary 3(2):117–122CrossRefPubMed

53.

Tateno T, Izumiyama H, Doi M, Akashi T, Ohno K, Hirata Y (2007) Defective expression of prohormone convertase 1/3 in silent corticotroph adenoma. Endocr J 54(5):777–782CrossRefPubMed

54.

Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y (2009) Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J 56(4):579–584CrossRefPubMed

55.

Ueyama T, Tamaki N, Kondoh T, Kurata H (1998) Large and invasive silent corticotroph-cell adenoma with elevated serum ACTH: a case report. Surg Neurol 50(1):30–31CrossRefPubMed

56.

Walsh MT, Couldwell WT (2010) Symptomatic cystic degeneration of a clinically silent corticotroph tumor of the pituitary gland. Skull Base 20(5):367–370CrossRefPubMedPubMedCentral

57.

Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T (2007) A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61(3):580–584CrossRefPubMed

58.

Yamakita N, Murai T, Kawamura S, Teramachi H, Matsuhisa T, Hirata T, Ikeda T, Morita H, Mune T, Yasuda K (1999) High molecular weight corticotropin measured with immunoradiometric assay in a patient with asymptomatic pituitary corticotropinoma. Endocr J 46(4):563–571CrossRefPubMed

59.

Yokoyama S, Kawahara Y, Sano T, Nakayama M, Kitajima S, Kuratsu J (2001) A case of non-functioning pituitary adenoma with Cushing’s syndrome upon recurrence. Neuropathology 21(4):288–293CrossRefPubMed

60.

Zoli M, Faustini-Fustini M, Mazzatenta D, Marucci G, De Carlo E, Bacci A, Pasquini E, Lanzino G, Frank G (2015) ACTH adenomas transforming their clinical expression: report of 5 cases. Neurosurg Focus 38(2):E15CrossRef

61.

Barr K, Pillinger DA, Miller CR, Wan Y, Sharpless JL (2016) ACTH staining does not predict retx in silent acth adenomas. Poster presentation, Endocrine Society Meeting SUN-487

62.

Bonner RA, Mukai K, Oppenheimer JH (1979) Two unusual variants of Nelson’s syndrome. J Clin Endocrinol Metab 49(1):23–29CrossRefPubMed

63.

Petrossians P, Ronci N, Valdes Socin H, Kalife A, Stevenaert A, Bloch B, Tabarin A, Beckers A (2001) ACTH silent adenoma shrinking under cabergoline. Eur J Endocrinol 144(1):51–57CrossRefPubMed

64.

Sahli R, Christ ER, Seiler R, Kappeler A, Vajtai I (2006) Clinicopathologic correlations of silent corticotroph adenomas of the pituitary: report of four cases and literature review. Pathol Res Pract 202(6):457–464CrossRefPubMed

65.

Salgado LR, Machado MC, Cukiert A, Liberman B, Kanamura CT, Alves VA (2006) Cushing’s disease arising from a clinically nonfunctioning pituitary adenoma. Endocr Pathol 17(2):191–199CrossRefPubMed

66.

Asano S, Ooka H, Okazaki R, Ishikawa T, Ochiai H, Nakashima M, Ide F, Hasegawa I, Miyawaki S, Nakaguchi H, Murakami M, Ogino Y, Takano K, Matsuno A (2007) Long-term remission of cyclic Cushing’s disease that was diagnosed and treated surgically in non-active phase. Endocr J 54(3):407–412CrossRefPubMed

67.

Popovic V, Micic D, Nesovic M, Howlett T, Doniach I, Kendereski A, Djordjevic P, Manojlovic D, Micic J, Besser M (1990) Cushing’s disease cycling over ten years. Exp Clin Endocrinol 96(2):143–148PubMed

68.

Ceccato F, Lombardi G, Manara R, Emanuelli E, Denaro L, Milanese L, Gardiman MP, Bertorelle R, Scanarini M, D’Avella D, Occhi G, Boscaro M, Zagonel V, Scaroni C (2015) Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. J Neurooncol 122(1):189–196CrossRefPubMed

69.

Nishioka H, Hirano A, Asa SL (1992) Silent corticotroph adenoma with multiple cysts: Pars intermedia tumor? Endocr Pathol 3(1):47–51CrossRef

70.

Kasuki L, Ventura N, Wildemberg L, Cardão Chimelli L, Gadelha M (2017) Accuracy of microcystic aspect on T2-weighted magnetic resonance imaging for the diagnosis of silent corticotropinomas. Presented at the 99th Endocrine Society Meeting, Orlando, April 2017 SAT 469

71.

Kovacs K, Lloyd R, Horvath E, Asa SL, Stefaneanu L, Killinger DW, Smyth HS (1989) Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. Am J Pathol 134(2):345–353PubMedPubMedCentral

72.

Cooper O, Melmed S (2012) Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab 26(4):447–460CrossRefPubMedPubMedCentral

73.

Sano T, Mader R, Asa SL, Qian ZR, Hino A, Yamada S (2003) “Honeycomb Golgi” in pituitary adenomas: not a marker of gonadotroph adenomas. Endocr Pathol 14(4):363–368CrossRefPubMed

74.

Jin L, Riss D, Ruebel K, Kajita S, Scheithauer BW, Horvath E, Kovacs K, Lloyd RV (2005) Galectin-3 expression in functioning and silent ACTH-producing adenomas. Endocr Pathol 16(2):107–114CrossRefPubMed

75.

Thodou E, Argyrakos T, Kontogeorgos G (2007) Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones 6(3):227–232

76.

Mete O, Hayhurst C, Alahmadi H, Monsalves E, Gucer H, Gentili F, Ezzat S, Asa SL, Zadeh G (2013) The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas. Endocr Pathol 24(4):191–198CrossRefPubMed

Titel: Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review
verfasst von: Fabienne Langlois
Dawn Shao Ting Lim
Chris G. Yedinak
Isabelle Cetas
Shirley McCartney
Justin Cetas
Aclan Dogan
Maria Fleseriu
Publikationsdatum: 14.10.2017
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 1/2018
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-017-0844-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Guidelines versus real life practice: the case of colonoscopy in acromegaly

Treatment of empty sella associated with visual impairment: a systematic review of chiasmapexy techniques

Association between FTO gene polymorphisms and HDL cholesterol concentration may cause higher risk of cardiovascular disease in patients with acromegaly

Genetic screening of regulatory regions of pituitary transcription factors in patients with idiopathic pituitary hormone deficiencies

Bone histomorphometry in acromegaly patients with fragility vertebral fractures